Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants

Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02708056

Enrollment

Registered

2016-03-15

Start date

2015-01-31

Completion date

2016-02-29

Last updated

2016-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Cancer

Keywords

Sugammadex, Rocuronium, Infant patients

Brief summary

The objective of this study is to evaluate the efficacy and safety of sugammadex in reversing profound neuromuscular block induced by rocuronium in infant patients

Interventions

DRUGSugammadex

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Months to 12 Months

Healthy volunteers

Inclusion criteria

* Patients between the ages of 1-12 month, * ASA physical status 1-3 who underwent elective brain cancer surgery during general anesthesia were included in the study

Exclusion criteria

* younger than 1month or older than 12 months. * hepatic or renal failure * A history of allergy to study medication

Design outcomes

Primary

Measure	Time frame
The efficacy of sugammadex were assessed by using Train of four (TOF)	1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026